Is Intuitive Surgical Stock Underperforming the Dow?

Core Viewpoint - Intuitive Surgical, Inc. (ISRG) is a significant player in the medical instruments and supplies industry, with a market capitalization of $175.4 billion, primarily known for its da Vinci Surgical System and other minimally invasive care products [1][2]. Financial Performance - ISRG's stock has retreated 18.2% from its 52-week high of $603.88, with a decline of 13.1% over the past three months, underperforming the Dow Jones Industrials Average's 5.9% increase during the same period [3]. - Year-to-date, ISRG shares have decreased by 12.8%, while the Dow has seen a 2.3% increase. Over the past year, ISRG's shares fell 16.4%, compared to the Dow's 13.2% returns [5]. - In Q4 2025, ISRG reported a revenue increase of 18.9% year-over-year to $2.9 billion, surpassing Wall Street estimates, attributed to higher procedure volumes and more da Vinci system placements. The adjusted EPS was $2.53, also beating estimates [6]. Competitive Landscape - Rival Becton, Dickinson and Company (BDX) has outperformed ISRG, growing 19.6% in 2026 and marginally over the past year [7]. - Among 31 analysts covering ISRG, the consensus rating is a "Moderate Buy," with a mean price target of $622.81, indicating a 26% upside potential from current price levels [7].